<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39331675</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1553-7358</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>PLoS computational biology</Title><ISOAbbreviation>PLoS Comput Biol</ISOAbbreviation></Journal><ArticleTitle>Effect of aberrant fructose metabolism following SARS-CoV-2 infection on colorectal cancer patients' poor prognosis.</ArticleTitle><Pagination><StartPage>e1012412</StartPage><MedlinePgn>e1012412</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1012412</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pcbi.1012412</ELocationID><Abstract><AbstractText>Most COVID-19 patients have a positive prognosis, but patients with additional underlying diseases are more likely to have severe illness and increased fatality rates. Numerous studies indicate that cancer patients are more prone to contract SARS-CoV-2 and develop severe COVID-19 or even dying. In the recent transcriptome investigations, it is demonstrated that the fructose metabolism is altered in patients with SARS-CoV-2 infection. However, cancer cells can use fructose as an extra source of energy for growth and metastasis. Furthermore, enhanced living conditions have resulted in a notable rise in fructose consumption in individuals' daily dietary habits. We therefore hypothesize that the poor prognosis of cancer patients caused by SARS-CoV-2 may therefore be mediated through fructose metabolism. Using CRC cases from four distinct cohorts, we built and validated a predictive model based on SARS-CoV-2 producing fructose metabolic anomalies by coupling Cox univariate regression and lasso regression feature selection algorithms to identify hallmark genes in colorectal cancer. We also developed a composite prognostic nomogram to improve clinical practice by integrating the characteristics of aberrant fructose metabolism produced by this novel coronavirus with age and tumor stage. To obtain the genes with the greatest potential prognostic values, LASSO regression analysis was performed, In the TCGA training cohort, patients were randomly separated into training and validation sets in the ratio of 4: 1, and the best risk score value for each sample was acquired by lasso regression analysis for further analysis, and the fifteen genes CLEC4A, FDFT1, CTNNB1, GPI, PMM2, PTPRD, IL7, ALDH3B1, AASS, AOC3, SEPINE1, PFKFB1, FTCD, TIMP1 and GATM were finally selected. In order to validate the model's accuracy, ROC curve analysis was performed on an external dataset, and the results indicated that the model had a high predictive power for the prognosis prediction of patients. Our study provides a theoretical foundation for the future targeted regulation of fructose metabolism in colorectal cancer patients, while simultaneously optimizing dietary guidance and therapeutic care for colorectal cancer patients in the context of the COVID-19 pandemic.</AbstractText><CopyrightInformation>Copyright: © 2024 Jiang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Jiaxin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8153-954X</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry &amp; Molecular Biology, China Medical University, Shenyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Xiaona</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Teaching Center for Basic Medical Experiment, China Medical University, Shenyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yibo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Bioinformatics, China Medical University, Shenyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuang</LastName><ForeName>Ziqian</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Bioinformatics, China Medical University, Shenyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Jing</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7478-0140</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry &amp; Molecular Biology, China Medical University, Shenyang, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Comput Biol</MedlineTA><NlmUniqueID>101238922</NlmUniqueID><ISSNLinking>1553-734X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>30237-26-4</RegistryNumber><NameOfSubstance UI="D005632">Fructose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005632" MajorTopicYN="Y">Fructose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049451" MajorTopicYN="N">Nomograms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>22</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>13</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39331675</ArticleId><ArticleId IdType="pmc">PMC11463760</ArticleId><ArticleId IdType="doi">10.1371/journal.pcbi.1012412</ArticleId><ArticleId IdType="pii">PCOMPBIOL-D-23-00881</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (albany NY). 2020;12(7):6049. doi: 10.18632/aging.103000</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.103000</ArticleId><ArticleId IdType="pmc">PMC7185114</ArticleId><ArticleId IdType="pubmed">32267833</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes research and clinical practice. 2020;162:108142. doi: 10.1016/j.diabres.2020.108142</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2020.108142</ArticleId><ArticleId IdType="pmc">PMC7144611</ArticleId><ArticleId IdType="pubmed">32278764</ArticleId></ArticleIdList></Reference><Reference><Citation>Moujaess E, Kourie HR, Ghosn M. Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. Critical reviews in oncology/hematology. 2020;150:102972. doi: 10.1016/j.critrevonc.2020.102972</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2020.102972</ArticleId><ArticleId IdType="pmc">PMC7174983</ArticleId><ArticleId IdType="pubmed">32344317</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al.. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 OutbreakPatients with Cancer in SARS-COV-2 Infection. Cancer discovery. 2020;10(6):783–91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309152</ArticleId><ArticleId IdType="pubmed">32345594</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Analysis of 92 deceased patients with COVID-19. Journal of medical virology. 2020;92(11):2511–5. doi: 10.1002/jmv.25891</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25891</ArticleId><ArticleId IdType="pmc">PMC7262332</ArticleId><ArticleId IdType="pubmed">32293741</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer. The lancet oncology. 2009;10(6):589–97. doi: 10.1016/S1470-2045(09)70069-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(09)70069-5</ArticleId><ArticleId IdType="pubmed">19482247</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee LY, Cazier J-B, Angelis V, Arnold R, Bisht V, Campton NA, et al.. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. The Lancet. 2020;395(10241):1919–26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255715</ArticleId><ArticleId IdType="pubmed">32473682</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Pina JM, Rodríguez Rodriguez M, Castro Quismondo N, Gil Manso R, Colmenares R, Gil Alos D, et al.. Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies. European Journal of Haematology. 2020;105(5):597–607. doi: 10.1111/ejh.13493</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.13493</ArticleId><ArticleId IdType="pubmed">32710500</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoumariyeh K, Biavasco F, Ihorst G, Rieg S, Nieters A, Kern WV, et al.. Covid-19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany. Cancer medicine. 2020;9(22):8412–22. doi: 10.1002/cam4.3460</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.3460</ArticleId><ArticleId IdType="pmc">PMC7666742</ArticleId><ArticleId IdType="pubmed">32931637</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsamakis K, Gavriatopoulou M, Schizas D, Stravodimou A, Mougkou A, Tsiptsios D, et al.. Oncology during the COVID-19 pandemic: challenges, dilemmas and the psychosocial impact on cancer patients. Oncology Letters. 2020;20(1):441–7. doi: 10.3892/ol.2020.11599</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2020.11599</ArticleId><ArticleId IdType="pmc">PMC7285823</ArticleId><ArticleId IdType="pubmed">32565968</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrò L, Peters S, Soria J-C, Di Giacomo AM, Barlesi F, Covre A, et al.. Challenges in lung cancer therapy during the COVID-19 pandemic. The Lancet Respiratory Medicine. 2020;8(6):542–4. doi: 10.1016/S2213-2600(20)30170-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30170-3</ArticleId><ArticleId IdType="pmc">PMC7146673</ArticleId><ArticleId IdType="pubmed">32278368</ArticleId></ArticleIdList></Reference><Reference><Citation>Dockter AG, Angelos GC. Molecular-based alternatives for colorectal cancer screening during the COVID-19 pandemic. Surgical technology international. 2020;36:143–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32347964</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Huang Y. Which type of cancer patients are more susceptible to the SARS-COX-2: evidence from a meta-analysis and bioinformatics analysis. Critical reviews in oncology/hematology. 2020;153:103032. doi: 10.1016/j.critrevonc.2020.103032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2020.103032</ArticleId><ArticleId IdType="pmc">PMC7295508</ArticleId><ArticleId IdType="pubmed">32599375</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Wang L, Chen Y, Wu Q, Chen G, Shen X, et al.. Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China. Cancer. 2020;126(17):4023–31. Epub 2020/06/24. doi: 10.1002/cncr.33042 ; PubMed Central PMCID: PMC7361610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.33042</ArticleId><ArticleId IdType="pmc">PMC7361610</ArticleId><ArticleId IdType="pubmed">32573776</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3):209–49. doi: 10.3322/caac.21660</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren X, Chen B, Hong Y, Liu W, Jiang Q, Yang J, et al.. The challenges in colorectal cancer management during COVID-19 epidemic. Annals of translational medicine. 2020;8(7). doi: 10.21037/atm.2020.03.158</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2020.03.158</ArticleId><ArticleId IdType="pmc">PMC7210180</ArticleId><ArticleId IdType="pubmed">32395542</ArticleId></ArticleIdList></Reference><Reference><Citation>Vecchione L, Stintzing S, Pentheroudakis G, Douillard J-Y, Lordick F. ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer. ESMO open. 2020;5:e000826. doi: 10.1136/esmoopen-2020-000826</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/esmoopen-2020-000826</ArticleId><ArticleId IdType="pmc">PMC7276236</ArticleId><ArticleId IdType="pubmed">32457036</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui TK, Leung K, Guo C-G, Tsui VW, Wu JT, Leung WK. Impacts of the coronavirus 2019 pandemic on gastrointestinal endoscopy volume and diagnosis of gastric and colorectal cancers: a population-based study. Gastroenterology. 2020;159(3):1164–6. e3. doi: 10.1053/j.gastro.2020.05.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.037</ArticleId><ArticleId IdType="pmc">PMC7230139</ArticleId><ArticleId IdType="pubmed">32425228</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzuu K, Misawa N, Ashikari K, Kessoku T, Kato S, Hosono K, et al.. Gastrointestinal Cancer Stage at Diagnosis Before and During the COVID-19 Pandemic in Japan. JAMA Netw Open. 2021;4(9):e2126334. Epub 2021/09/22. doi: 10.1001/jamanetworkopen.2021.26334 ; PubMed Central PMCID: PMC8456386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.26334</ArticleId><ArticleId IdType="pmc">PMC8456386</ArticleId><ArticleId IdType="pubmed">34546368</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkons NR, Kim C, Boedec C, Keele LJ, Schneider C, Teitelbaum UR, et al.. Quantifying the impact of the COVID-19 pandemic on gastrointestinal cancer care delivery. Cancer Rep (Hoboken). 2022;5(1):e1427. Epub 2021/06/18. doi: 10.1002/cnr2.1427 ; PubMed Central PMCID: PMC8420475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cnr2.1427</ArticleId><ArticleId IdType="pmc">PMC8420475</ArticleId><ArticleId IdType="pubmed">34137216</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinspan LT, Rustgi SD, Itzkowitz SH, Polydorides AD, Lucas AL. Impact of COVID-19 pandemic on gastrointestinal cancer diagnosis and resection: An observational study. Clin Res Hepatol Gastroenterol. 2022;46(3):101839. Epub 2021/11/26. doi: 10.1016/j.clinre.2021.101839 ; PubMed Central PMCID: PMC8608414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinre.2021.101839</ArticleId><ArticleId IdType="pmc">PMC8608414</ArticleId><ArticleId IdType="pubmed">34823067</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro LC, Thakkar A, Campbell ST, Forest SK, Pradhan K, Gonzalez-Lugo JD, et al.. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Cancer Cell. 2022;40(1):3–5. Epub 2021/11/29. doi: 10.1016/j.ccell.2021.11.006 ; PubMed Central PMCID: PMC8595142 and is on the faculty at Physicians’ Education Research. A.V. has received research funding from GlaxoSmithKline, BMS, Janssen, Incyte, MedPacto, Celgene, Novartis, Curis, Prelude, and Eli Lilly and Company; has received compensation as a scientific advisor to Novartis, Stelexis Therapeutics, Acceleron Pharma, and Celgene; and has equity ownership in Stelexis Therapeutics. All other authors declare no competing interests.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2021.11.006</ArticleId><ArticleId IdType="pmc">PMC8595142</ArticleId><ArticleId IdType="pubmed">34838186</ArticleId></ArticleIdList></Reference><Reference><Citation>Ligumsky H, Dor H, Etan T, Golomb I, Nikolaevski-Berlin A, Greenberg I, et al.. Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer. Lancet Oncol. 2022;23(2):193–5. Epub 2021/12/27. doi: 10.1016/S1470-2045(21)00715-4 ; PubMed Central PMCID: PMC8700280 work. AS is partially supported by the Israeli Council for Higher Education via the Weizmann Data Science Research Center, and by a research grant from the Estate of Tully and Michele Plesser. IW reports speaker fees and fees for consultancy from Roche, Bristol Myers Squibb, Merck Sharp &amp; Dohme, Beyond Air, AstraZeneca, and Novartis; contracts or research funding from Roche, Novatis, Beyond Air, and Merck Sharp &amp; Dohme; participation on a data safety monitoring board or advisory board of Merck Sharp &amp; Dohme and AstraZeneca; participation in committee of Israeli Cancer Association; and stock options in Breath of life. All other authors declare no competing interests. COVI3 study investigators are listed at the appendix (p 4).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(21)00715-4</ArticleId><ArticleId IdType="pmc">PMC8700280</ArticleId><ArticleId IdType="pubmed">34953523</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo A, Palmiotti G. SARS-CoV-2 Omicron variant in cancer patients: an insight into the vaccine booster debate. Future Oncol. 2022;18(11):1301–2. Epub 2022/02/04. doi: 10.2217/fon-2022-0024 ; PubMed Central PMCID: PMC8826832.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fon-2022-0024</ArticleId><ArticleId IdType="pmc">PMC8826832</ArticleId><ArticleId IdType="pubmed">35109688</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al.. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271–80.e8. doi: 10.1016/j.cell.2020.02.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281–92.e6. doi: 10.1016/j.cell.2020.02.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.058</ArticleId><ArticleId IdType="pmc">PMC7102599</ArticleId><ArticleId IdType="pubmed">32155444</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al.. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Critical Care. 2020;24(1). doi: 10.1186/s13054-020-03120-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03120-0</ArticleId><ArticleId IdType="pmc">PMC7356137</ArticleId><ArticleId IdType="pubmed">32660650</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung WK, To K-f, Chan PKS, Chan HLY, Wu AKL, Lee N, et al.. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology. 2003;125(4):1011–7. doi: 10.1016/s0016-5085(03)01215-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0016-5085(03)01215-0</ArticleId><ArticleId IdType="pmc">PMC7126982</ArticleId><ArticleId IdType="pubmed">14517783</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Kang Z, Gong H, Xu D, Wang J, Li Z, et al.. Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process. Gut. 2020;69(6):1010–8. doi: 10.1136/gutjnl-2020-320953</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-320953</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497–506. doi: 10.1016/s0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z, et al.. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut. 2020;69(6):997–1001. doi: 10.1136/gutjnl-2020-321013</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-321013</ArticleId><ArticleId IdType="pubmed">32241899</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Guo C, Tang L, Hong Z, Zhou J, Dong X, et al.. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. The Lancet Gastroenterology &amp; Hepatology. 2020;5(5):434–5. doi: 10.1016/S2468-1253(20)30083-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30083-2</ArticleId><ArticleId IdType="pmc">PMC7158584</ArticleId><ArticleId IdType="pubmed">32199469</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhary M. COVID-19 susceptibility: potential of ACE2 polymorphisms. Egyptian Journal of Medical Human Genetics. 2020;21(1). doi: 10.1186/s43042-020-00099-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43042-020-00099-9</ArticleId><ArticleId IdType="pmc">PMC7502288</ArticleId><ArticleId IdType="pubmed">38624559</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira Andrade JM, Paraíso AF, Garcia ZM, Ferreira AVM, Sinisterra RDM, Sousa FB, et al.. Cross talk between angiotensin-(1–7)/Mas axis and sirtuins in adipose tissue and metabolism of high-fat feed mice. Peptides. 2014;55:158–65. doi: 10.1016/j.peptides.2014.03.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2014.03.006</ArticleId><ArticleId IdType="pubmed">24642355</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H-R, Tain Y-L, Tiao M-M, Chen C-C, Sheen J-M, Lin IC, et al.. Prenatal dexamethasone and postnatal high-fat diet have a synergistic effect of elevating blood pressure through a distinct programming mechanism of systemic and adipose renin–angiotensin systems. Lipids in Health and Disease. 2018;17(1). doi: 10.1186/s12944-018-0701-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12944-018-0701-0</ArticleId><ArticleId IdType="pmc">PMC5853160</ArticleId><ArticleId IdType="pubmed">29540174</ArticleId></ArticleIdList></Reference><Reference><Citation>Bundalo MM, Zivkovic MD, Romic SD, Tepavcevic SN, Koricanac GB, Djuric TM, et al.. Fructose-rich diet induces gender-specific changes in expression of the renin–angiotensin system in rat heart and upregulates the ACE/AT1R axis in the male rat aorta. Journal of the Renin-Angiotensin-Aldosterone System. 2016;17(2). doi: 10.1177/1470320316642915</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1470320316642915</ArticleId><ArticleId IdType="pmc">PMC5843877</ArticleId><ArticleId IdType="pubmed">27121972</ArticleId></ArticleIdList></Reference><Reference><Citation>Maynard ND, Gutschow MV, Birch EW, Covert MW. The virus as metabolic engineer. Biotechnol J. 2010;5(7):686–94. Epub 2010/07/29. doi: 10.1002/biot.201000080 ; PubMed Central PMCID: PMC3004434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biot.201000080</ArticleId><ArticleId IdType="pmc">PMC3004434</ArticleId><ArticleId IdType="pubmed">20665642</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaker SK, Ch’ng J, Christofk HR. Viral hijacking of cellular metabolism. BMC Biol. 2019;17(1):59. Epub 2019/07/20. doi: 10.1186/s12915-019-0678-9 ; PubMed Central PMCID: PMC6637495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12915-019-0678-9</ArticleId><ArticleId IdType="pmc">PMC6637495</ArticleId><ArticleId IdType="pubmed">31319842</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh Y, Trautwein C, Fendel R, Krickeberg N, Berezhnoy G, Bissinger R, et al.. SARS-CoV-2 infection paralyzes cytotoxic and metabolic functions of the immune cells. Heliyon. 2021;7(6). doi: 10.1016/j.heliyon.2021.e07147</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2021.e07147</ArticleId><ArticleId IdType="pmc">PMC8159709</ArticleId><ArticleId IdType="pubmed">34075347</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal N, Agrawal S, Agrawal A. High fructose-induced metabolic changes enhance inflammation in human dendritic cells. Clinical and Experimental Immunology. 2019;197(2):237–49. doi: 10.1111/cei.13299</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13299</ArticleId><ArticleId IdType="pmc">PMC6642875</ArticleId><ArticleId IdType="pubmed">30919933</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardinassi LG, Souza COS, Sales-Campos H, Fonseca SG. Immune and Metabolic Signatures of COVID-19 Revealed by Transcriptomics Data Reuse. Frontiers in Immunology. 2020;11. doi: 10.3389/fimmu.2020.01636</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01636</ArticleId><ArticleId IdType="pmc">PMC7332781</ArticleId><ArticleId IdType="pubmed">32670298</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Shu T, Yang X. Plasma metabolomic and lipidomic alterations associated with COVID-19. Natl Sci Rev. 2020. doi: 10.1093/nsr/nwaa086</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nsr/nwaa086</ArticleId><ArticleId IdType="pmc">PMC7197563</ArticleId><ArticleId IdType="pubmed">34676128</ArticleId></ArticleIdList></Reference><Reference><Citation>Strober JW, Brady MJ. Dietary fructose consumption and triple-negative breast cancer incidence. Frontiers in Endocrinology. 2019;10:367. doi: 10.3389/fendo.2019.00367</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2019.00367</ArticleId><ArticleId IdType="pmc">PMC6581676</ArticleId><ArticleId IdType="pubmed">31244777</ArticleId></ArticleIdList></Reference><Reference><Citation>Carreño D, Corro N, Torres-Estay V, Véliz LP, Jaimovich R, Cisternas P, et al.. Fructose and prostate cancer: toward an integrated view of cancer cell metabolism. Prostate cancer and prostatic diseases. 2019;22(1):49–58. doi: 10.1038/s41391-018-0072-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41391-018-0072-7</ArticleId><ArticleId IdType="pubmed">30104655</ArticleId></ArticleIdList></Reference><Reference><Citation>Budhraja A, Basu A, Gheware A, Abhilash D, Rajagopala S, Pakala S, et al.. Molecular signature of postmortem lung tissue from COVID-19 patients suggests distinct trajectories driving mortality. Dis Model Mech. 2022;15(5). Epub 2022/04/20. doi: 10.1242/dmm.049572 ; PubMed Central PMCID: PMC9194484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.049572</ArticleId><ArticleId IdType="pmc">PMC9194484</ArticleId><ArticleId IdType="pubmed">35438176</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheffer M, Bacolod MD, Zuk O, Giardina SF, Pincas H, Barany F, et al.. Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A. 2009;106(17):7131–6. Epub 2009/04/11. doi: 10.1073/pnas.0902232106 ; PubMed Central PMCID: PMC2678450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0902232106</ArticleId><ArticleId IdType="pmc">PMC2678450</ArticleId><ArticleId IdType="pubmed">19359472</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin ML, Zeng Z, Adileh M, Jacobo A, Li C, Vakiani E, et al.. Logarithmic expansion of LGR5(+) cells in human colorectal cancer. Cell Signal. 2018;42:97–105. Epub 2017/09/30. doi: 10.1016/j.cellsig.2017.09.018 ; PubMed Central PMCID: PMC5766032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2017.09.018</ArticleId><ArticleId IdType="pmc">PMC5766032</ArticleId><ArticleId IdType="pubmed">28958617</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, et al.. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 2010;138(3):958–68. Epub 2009/11/17. doi: 10.1053/j.gastro.2009.11.005 ; PubMed Central PMCID: PMC3388775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2009.11.005</ArticleId><ArticleId IdType="pmc">PMC3388775</ArticleId><ArticleId IdType="pubmed">19914252</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman TJ, Smith JJ, Chen X, Washington MK, Roland JT, Means AL, et al.. Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of β-catenin. Gastroenterology. 2012;142(3):562–71.e2. Epub 2011/11/26. doi: 10.1053/j.gastro.2011.11.026 ; PubMed Central PMCID: PMC3343368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2011.11.026</ArticleId><ArticleId IdType="pmc">PMC3343368</ArticleId><ArticleId IdType="pubmed">22115830</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams CS, Bernard JK, Demory Beckler M, Almohazey D, Washington MK, Smith JJ, et al.. ERBB4 is over-expressed in human colon cancer and enhances cellular transformation. Carcinogenesis. 2015;36(7):710–8. Epub 2015/04/29. doi: 10.1093/carcin/bgv049 ; PubMed Central PMCID: PMC4572918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/bgv049</ArticleId><ArticleId IdType="pmc">PMC4572918</ArticleId><ArticleId IdType="pubmed">25916654</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen MS, Lo YH, Chen X, Williams CS, Donnelly JM, Criss ZK, 2nd, et al.. Growth Factor-Independent 1 Is a Tumor Suppressor Gene in Colorectal Cancer. Mol Cancer Res. 2019;17(3):697–708. Epub 2019/01/05. doi: 10.1158/1541-7786.MCR-18-0666 ; PubMed Central PMCID: PMC7387124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1541-7786.MCR-18-0666</ArticleId><ArticleId IdType="pmc">PMC7387124</ArticleId><ArticleId IdType="pubmed">30606770</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 2014;27:1–7. Epub 2014/01/15. doi: 10.1016/j.coi.2013.12.005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2013.12.005</ArticleId><ArticleId IdType="pubmed">24413387</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–70. Epub 2011/03/26. doi: 10.1126/science.1203486 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1203486</ArticleId><ArticleId IdType="pubmed">21436444</ArticleId></ArticleIdList></Reference><Reference><Citation>Palucka AK, Coussens LM. The Basis of Oncoimmunology. Cell. 2016;164(6):1233–47. Epub 2016/03/12. doi: 10.1016/j.cell.2016.01.049 ; PubMed Central PMCID: PMC4788788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.01.049</ArticleId><ArticleId IdType="pmc">PMC4788788</ArticleId><ArticleId IdType="pubmed">26967289</ArticleId></ArticleIdList></Reference><Reference><Citation>Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99. Epub 2010/03/23. doi: 10.1016/j.cell.2010.01.025 ; PubMed Central PMCID: PMC2866629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.01.025</ArticleId><ArticleId IdType="pmc">PMC2866629</ArticleId><ArticleId IdType="pubmed">20303878</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel AE, Drijvers JM, Baker GJ, Catozzi A, García-Cañaveras JC, Gassaway BM, et al.. Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity. Cell. 2020;183(7):1848–66.e26. Epub 2020/12/11. doi: 10.1016/j.cell.2020.11.009 ; PubMed Central PMCID: PMC8064125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.11.009</ArticleId><ArticleId IdType="pmc">PMC8064125</ArticleId><ArticleId IdType="pubmed">33301708</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Biase S, Lee C, Brandhorst S, Manes B, Buono R, Cheng CW, et al.. Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity. Cancer Cell. 2016;30(1):136–46. Epub 2016/07/15. doi: 10.1016/j.ccell.2016.06.005 ; PubMed Central PMCID: PMC5388544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2016.06.005</ArticleId><ArticleId IdType="pmc">PMC5388544</ArticleId><ArticleId IdType="pubmed">27411588</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, et al.. Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. Cancer Cell. 2016;30(1):147–60. Epub 2016/07/15. doi: 10.1016/j.ccell.2016.05.016 ; PubMed Central PMCID: PMC5715805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2016.05.016</ArticleId><ArticleId IdType="pmc">PMC5715805</ArticleId><ArticleId IdType="pubmed">27411589</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio-Patiño C, Bossowski JP, De Donatis GM, Mondragón L, Villa E, Aira LE, et al.. Low-Protein Diet Induces IRE1α-Dependent Anticancer Immunosurveillance. Cell Metab. 2018;27(4):828–42.e7. Epub 2018/03/20. doi: 10.1016/j.cmet.2018.02.009 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2018.02.009</ArticleId><ArticleId IdType="pubmed">29551590</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesh GV, Mohanram RK. Metabolic reprogramming and immune regulation in viral diseases. Rev Med Virol. 2022;32(2):e2268. Epub 2021/06/28. doi: 10.1002/rmv.2268 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2268</ArticleId><ArticleId IdType="pubmed">34176174</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, et al.. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol. 2003;4(12):1206–12. Epub 2003/10/28. doi: 10.1038/ni1003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1003</ArticleId><ArticleId IdType="pubmed">14578884</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayres JS. A metabolic handbook for the COVID-19 pandemic. Nat Metab. 2020;2(7):572–85. Epub 2020/07/23. doi: 10.1038/s42255-020-0237-2 ; PubMed Central PMCID: PMC7325641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-020-0237-2</ArticleId><ArticleId IdType="pmc">PMC7325641</ArticleId><ArticleId IdType="pubmed">32694793</ArticleId></ArticleIdList></Reference><Reference><Citation>Berber E, Sumbria D, Rouse BT. Could targeting immunometabolism be a way to control the burden of COVID-19 infection? Microbes Infect. 2021;23(2–3):104780. Epub 2021/01/23. doi: 10.1016/j.micinf.2021.104780 ; PubMed Central PMCID: PMC7816601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2021.104780</ArticleId><ArticleId IdType="pmc">PMC7816601</ArticleId><ArticleId IdType="pubmed">33482357</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas-Rüddel D, Winning J, Dickmann P, Ouart D, Kortgen A, Janssens U, et al.. Coronavirus disease 2019 (COVID-19): update for anesthesiologists and intensivists March 2020. Anaesthesist. 2021;70(Suppl 1):1–10. Epub 2020/03/27. doi: 10.1007/s00101-020-00760-3 ; PubMed Central PMCID: PMC7095212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00101-020-00760-3</ArticleId><ArticleId IdType="pmc">PMC7095212</ArticleId><ArticleId IdType="pubmed">32211920</ArticleId></ArticleIdList></Reference><Reference><Citation>Bost P, Giladi A, Liu Y, Bendjelal Y, Xu G, David E, et al.. Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients. Cell. 2020;181(7):1475–88.e12. Epub 2020/06/02. doi: 10.1016/j.cell.2020.05.006 ; PubMed Central PMCID: PMC7205692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.006</ArticleId><ArticleId IdType="pmc">PMC7205692</ArticleId><ArticleId IdType="pubmed">32479746</ArticleId></ArticleIdList></Reference><Reference><Citation>Codo AC, Davanzo GG, Monteiro LB, de Souza GF, Muraro SP, Virgilio-da-Silva JV, et al.. Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis. Cell Metab. 2020;32(3):437–46.e5. Epub 2020/07/23. doi: 10.1016/j.cmet.2020.07.007 ; PubMed Central PMCID: PMC7367032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2020.07.007</ArticleId><ArticleId IdType="pmc">PMC7367032</ArticleId><ArticleId IdType="pubmed">32697943</ArticleId></ArticleIdList></Reference><Reference><Citation>Haspel JA, Anafi R, Brown MK, Cermakian N, Depner C, Desplats P, et al.. Perfect timing: circadian rhythms, sleep, and immunity—an NIH workshop summary. JCI Insight. 2020;5(1). doi: 10.1172/jci.insight.131487</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.131487</ArticleId><ArticleId IdType="pmc">PMC7030790</ArticleId><ArticleId IdType="pubmed">31941836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraris RP, Choe J-y, Patel CR. Intestinal absorption of fructose. Annual review of nutrition. 2018;38:41. doi: 10.1146/annurev-nutr-082117-051707</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-nutr-082117-051707</ArticleId><ArticleId IdType="pmc">PMC6457363</ArticleId><ArticleId IdType="pubmed">29751733</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson PR, Shepherd SJ. Personal view: food for thought—western lifestyle and susceptibility to Crohn’s disease. The FODMAP hypothesis. Alimentary Pharmacology and Therapeutics. 2005;21(12):1399–409. doi: 10.1111/j.1365-2036.2005.02506.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2005.02506.x</ArticleId><ArticleId IdType="pubmed">15948806</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalves MD, Lu C, Tutnauer J, Hartman TE, Hwang S-K, Murphy CJ, et al.. High-fructose corn syrup enhances intestinal tumor growth in mice. Science. 2019;363(6433):1345–9. doi: 10.1126/science.aat8515</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aat8515</ArticleId><ArticleId IdType="pmc">PMC6487857</ArticleId><ArticleId IdType="pubmed">30898933</ArticleId></ArticleIdList></Reference><Reference><Citation>Douard V, Ferraris RP. Regulation of the fructose transporter GLUT5 in health and disease. American Journal of Physiology-Endocrinology and Metabolism. 2008;295(2):E227–E37. doi: 10.1152/ajpendo.90245.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.90245.2008</ArticleId><ArticleId IdType="pmc">PMC2652499</ArticleId><ArticleId IdType="pubmed">18398011</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris DS, Slot JW, Geuze HJ, James DE. Polarized distribution of glucose transporter isoforms in Caco-2 cells. Proceedings of the National Academy of Sciences. 1992;89(16):7556–60. doi: 10.1073/pnas.89.16.7556</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.16.7556</ArticleId><ArticleId IdType="pmc">PMC49749</ArticleId><ArticleId IdType="pubmed">1502167</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahraoui L, Rousset M, Dussaulx E, Darmoul D, Zweibaum A, Brot-Laroche E. Expression and localization of GLUT-5 in Caco-2 cells, human small intestine, and colon. American Journal of Physiology-Gastrointestinal and Liver Physiology. 1992;263(3):G312–G8. doi: 10.1152/ajpgi.1992.263.3.G312</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.1992.263.3.G312</ArticleId><ArticleId IdType="pubmed">1384349</ArticleId></ArticleIdList></Reference><Reference><Citation>Godoy A, Ulloa V, Rodríguez F, Reinicke K, Yañez AJ, García Mde L, et al.. Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol. 2006;207(3):614–27. Epub 2006/03/09. doi: 10.1002/jcp.20606 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.20606</ArticleId><ArticleId IdType="pubmed">16523487</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Li Y, Xu J, Wang S, Xu Y, Li X, et al.. Aldolase B Overexpression is Associated with Poor Prognosis and Promotes Tumor Progression by Epithelial-Mesenchymal Transition in Colorectal Adenocarcinoma. Cell Physiol Biochem. 2017;42(1):397–406. Epub 2017/05/31. doi: 10.1159/000477484 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000477484</ArticleId><ArticleId IdType="pubmed">28558381</ArticleId></ArticleIdList></Reference><Reference><Citation>Uzozie A, Nanni P, Staiano T, Grossmann J, Barkow-Oesterreicher S, Shay JW, et al.. Sorbitol dehydrogenase overexpression and other aspects of dysregulated protein expression in human precancerous colorectal neoplasms: a quantitative proteomics study. Mol Cell Proteomics. 2014;13(5):1198–218. Epub 2014/02/26. doi: 10.1074/mcp.M113.035105 ; PubMed Central PMCID: PMC4014279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M113.035105</ArticleId><ArticleId IdType="pmc">PMC4014279</ArticleId><ArticleId IdType="pubmed">24567419</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravich WJ, Bayless TM, Thomas M. Fructose: incomplete intestinal absorption in humans. Gastroenterology. 1983;84(1):26–9. Epub 1983/01/01. .</Citation><ArticleIdList><ArticleId IdType="pubmed">6847852</ArticleId></ArticleIdList></Reference><Reference><Citation>Rumessen JJ, Gudmand-Høyer E. Absorption capacity of fructose in healthy adults. Comparison with sucrose and its constituent monosaccharides. Gut. 1986;27(10):1161–8. Epub 1986/10/01. doi: 10.1136/gut.27.10.1161 ; PubMed Central PMCID: PMC1433856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.27.10.1161</ArticleId><ArticleId IdType="pmc">PMC1433856</ArticleId><ArticleId IdType="pubmed">3781328</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer PL, Caviar EM, McCallum RW. Fructose intake at current levels in the United States may cause gastrointestinal distress in normal adults. J Am Diet Assoc. 2005;105(10):1559–66. Epub 2005/09/27. doi: 10.1016/j.jada.2005.07.002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jada.2005.07.002</ArticleId><ArticleId IdType="pubmed">16183355</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang C, Hui S, Lu W, Cowan AJ, Morscher RJ, Lee G, et al.. The Small Intestine Converts Dietary Fructose into Glucose and Organic Acids. Cell Metab. 2018;27(2):351–61.e3. Epub 2018/02/08. doi: 10.1016/j.cmet.2017.12.016 ; PubMed Central PMCID: PMC6032988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2017.12.016</ArticleId><ArticleId IdType="pmc">PMC6032988</ArticleId><ArticleId IdType="pubmed">29414685</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalves MD, Lu C, Tutnauer J, Hartman TE, Hwang SK, Murphy CJ, et al.. High-fructose corn syrup enhances intestinal tumor growth in mice. Science. 2019;363(6433):1345–9. Epub 2019/03/23. doi: 10.1126/science.aat8515 ; PubMed Central PMCID: PMC6487857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aat8515</ArticleId><ArticleId IdType="pmc">PMC6487857</ArticleId><ArticleId IdType="pubmed">30898933</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Huang D, McArthur DL, Boros LG, Nissen N, Heaney AP. Fructose Induces Transketolase Flux to Promote Pancreatic Cancer GrowthFructose Induces Pancreatic Cancer Growth. Cancer research. 2010;70(15):6368–76.</Citation><ArticleIdList><ArticleId IdType="pubmed">20647326</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng Y, Fan X, Bai Y, Wang S, Huang H, Yang H, et al.. SLC2A5 promotes lung adenocarcinoma cell growth and metastasis by enhancing fructose utilization. Cell Death Discovery. 2018;4(1):1–12. doi: 10.1038/s41420-018-0038-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-018-0038-5</ArticleId><ArticleId IdType="pmc">PMC5841403</ArticleId><ArticleId IdType="pubmed">29531835</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu P, Chen K-Y, Xiang K, Johnson C, Crown SB, Rakhilin N, et al.. Aldolase B-mediated fructose metabolism drives metabolic reprogramming of colon cancer liver metastasis. Cell metabolism. 2018;27(6):1249–62. e4. doi: 10.1016/j.cmet.2018.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2018.04.003</ArticleId><ArticleId IdType="pmc">PMC5990465</ArticleId><ArticleId IdType="pubmed">29706565</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W-L, Wang Y-Y, Zhao A, Xia L, Xie G, Su M, et al.. Enhanced fructose utilization mediated by SLC2A5 is a unique metabolic feature of acute myeloid leukemia with therapeutic potential. Cancer cell. 2016;30(5):779–91. doi: 10.1016/j.ccell.2016.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2016.09.006</ArticleId><ArticleId IdType="pmc">PMC5496656</ArticleId><ArticleId IdType="pubmed">27746145</ArticleId></ArticleIdList></Reference><Reference><Citation>Su C, Li H, Gao W. GLUT5 increases fructose utilization and promotes tumor progression in glioma. Biochemical and biophysical research communications. 2018;500(2):462–9. doi: 10.1016/j.bbrc.2018.04.103</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2018.04.103</ArticleId><ArticleId IdType="pubmed">29660339</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan MR, Danai LV, Lewis CA, Chan SH, Gui DY, Kunchok T, et al.. Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. Elife. 2019;8:e44235. doi: 10.7554/eLife.44235</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.44235</ArticleId><ArticleId IdType="pmc">PMC6510537</ArticleId><ArticleId IdType="pubmed">30990168</ArticleId></ArticleIdList></Reference><Reference><Citation>Softic S, Gupta MK, Wang G-X, Fujisaka S, O’Neill BT, Rao TN, et al.. Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling. The Journal of clinical investigation. 2017;127(11):4059–74. doi: 10.1172/JCI94585</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI94585</ArticleId><ArticleId IdType="pmc">PMC5663363</ArticleId><ArticleId IdType="pubmed">28972537</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman MA, Samuel VT. The sweet path to metabolic demise: fructose and lipid synthesis. Trends in Endocrinology &amp; Metabolism. 2016;27(10):719–30. doi: 10.1016/j.tem.2016.06.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2016.06.005</ArticleId><ArticleId IdType="pmc">PMC5035631</ArticleId><ArticleId IdType="pubmed">27387598</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo H-Y, Wallig MA, Chung BH, Nara TY, Cho BS, Nakamura MT. Dietary fructose induces a wide range of genes with distinct shift in carbohydrate and lipid metabolism in fed and fasted rat liver. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2008;1782(5):341–8. doi: 10.1016/j.bbadis.2008.02.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2008.02.007</ArticleId><ArticleId IdType="pubmed">18346472</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo H-Y, Miyashita M, Cho BS, Nakamura MT. Replacing dietary glucose with fructose increases ChREBP activity and SREBP-1 protein in rat liver nucleus. Biochemical and biophysical research communications. 2009;390(2):285–9. doi: 10.1016/j.bbrc.2009.09.109</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2009.09.109</ArticleId><ArticleId IdType="pubmed">19799862</ArticleId></ArticleIdList></Reference><Reference><Citation>Hieronimus B, Medici V, Bremer AA, Lee V, Nunez MV, Sigala DM, et al.. Synergistic effects of fructose and glucose on lipoprotein risk factors for cardiovascular disease in young adults. Metabolism. 2020;112:154356. doi: 10.1016/j.metabol.2020.154356</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2020.154356</ArticleId><ArticleId IdType="pmc">PMC8744004</ArticleId><ArticleId IdType="pubmed">32916151</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Wong CW, Chiles EN, Mellinger AL, Bae H, Jung S, et al.. Glycerate from intestinal fructose metabolism induces islet cell damage and glucose intolerance. Cell Metabolism. 2022. doi: 10.1016/j.cmet.2022.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2022.05.007</ArticleId><ArticleId IdType="pmc">PMC9897509</ArticleId><ArticleId IdType="pubmed">35688154</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro A, Mu W, Roncal C, Cheng K-Y, Johnson RJ, Scarpace PJ. Fructose-induced leptin resistance exacerbates weight gain in response to subsequent high-fat feeding. American journal of physiology-regulatory, integrative and comparative physiology. 2008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2584858</ArticleId><ArticleId IdType="pubmed">18703413</ArticleId></ArticleIdList></Reference><Reference><Citation>Teff KL, Elliott SS, Tschöp M, Kieffer TJ, Rader D, Heiman M, et al.. Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. The Journal of Clinical Endocrinology &amp; Metabolism. 2004;89(6):2963–72.</Citation><ArticleIdList><ArticleId IdType="pubmed">15181085</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al.. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–6. doi: 10.1038/s41586-020-2521-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. How obesity could create problems for a COVID vaccine. Nature. 2020;586(7830):488–90. doi: 10.1038/d41586-020-02946-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-02946-6</ArticleId><ArticleId IdType="pubmed">33082543</ArticleId></ArticleIdList></Reference><Reference><Citation>Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nature reviews Gastroenterology &amp; hepatology. 2019;16(12):713–32. doi: 10.1038/s41575-019-0189-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-019-0189-8</ArticleId><ArticleId IdType="pubmed">31455888</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, et al.. Caloric restriction mimetics enhance anticancer immunosurveillance. Cancer cell. 2016;30(1):147–60. doi: 10.1016/j.ccell.2016.05.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2016.05.016</ArticleId><ArticleId IdType="pmc">PMC5715805</ArticleId><ArticleId IdType="pubmed">27411589</ArticleId></ArticleIdList></Reference><Reference><Citation>Barone S, Fussell SL, Singh AK, Lucas F, Xu J, Kim C, et al.. Slc2a5 (Glut5) is essential for the absorption of fructose in the intestine and generation of fructose-induced hypertension. Journal of Biological Chemistry. 2009;284(8):5056–66. doi: 10.1074/jbc.M808128200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M808128200</ArticleId><ArticleId IdType="pmc">PMC2643499</ArticleId><ArticleId IdType="pubmed">19091748</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez A, Naljayan M, Shuja I, Florea A, Reisin E. Hypertension, obesity, and COVID-19: A collision of pandemics. Current Hypertension Reports. 2021;23(6):1–7. doi: 10.1007/s11906-021-01153-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11906-021-01153-6</ArticleId><ArticleId IdType="pmc">PMC8241408</ArticleId><ArticleId IdType="pubmed">34189678</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dorst DC, Dobbin SJ, Neves KB, Herrmann J, Herrmann SM, Versmissen J, et al.. Hypertension and prohypertensive antineoplastic therapies in cancer patients. Circulation research. 2021;128(7):1040–61. doi: 10.1161/CIRCRESAHA.121.318051</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.121.318051</ArticleId><ArticleId IdType="pmc">PMC8011349</ArticleId><ArticleId IdType="pubmed">33793337</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang IS, Ho H, Hoffman BB, Reaven GM. Fructose-induced insulin resistance and hypertension in rats. Hypertension. 1987;10(5):512–6. Epub 1987/11/01. doi: 10.1161/01.hyp.10.5.512 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.hyp.10.5.512</ArticleId><ArticleId IdType="pubmed">3311990</ArticleId></ArticleIdList></Reference><Reference><Citation>Reaven GM. Role of Insulin Resistance in Human Disease. Diabetes. 1988;37(12):1595–607. doi: 10.2337/diab.37.12.1595</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diab.37.12.1595</ArticleId><ArticleId IdType="pubmed">3056758</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleder J, Chen YD, Cully MD, Reaven GM. Hyperinsulinemia in fructose-induced hypertriglyceridemia in the rat. Metabolism. 1980;29(4):303–5. Epub 1980/04/01. doi: 10.1016/0026-0495(80)90001-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0026-0495(80)90001-3</ArticleId><ArticleId IdType="pubmed">6990170</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobey TA, Greenfield M, Kraemer F, Reaven GM. Relationship between insulin resistance, insulin secretion, very low density lipoprotein kinetics, and plasma triglyceride levels in normotriglyceridemic man. Metabolism. 1981;30(2):165–71. Epub 1981/02/01. doi: 10.1016/0026-0495(81)90167-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0026-0495(81)90167-0</ArticleId><ArticleId IdType="pubmed">7007804</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayres JS, Schneider DS. Tolerance of infections. Annu Rev Immunol. 2012;30:271–94. Epub 2012/01/10. doi: 10.1146/annurev-immunol-020711-075030 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-020711-075030</ArticleId><ArticleId IdType="pubmed">22224770</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohrabi Y, Reinecke H, Godfrey R. Altered Cholesterol and Lipid Synthesis Mediates Hyperinflammation in COVID-19. Trends Endocrinol Metab. 2021;32(3):132–4. Epub 2021/01/19. doi: 10.1016/j.tem.2021.01.001 ; PubMed Central PMCID: PMC7833986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2021.01.001</ArticleId><ArticleId IdType="pmc">PMC7833986</ArticleId><ArticleId IdType="pubmed">33455862</ArticleId></ArticleIdList></Reference><Reference><Citation>Abstracts of Presentations at the Association of Clinical Scientists 143(rd) Meeting Louisville, KY May 11–14,2022. Ann Clin Lab Sci. 2022;52(3):511–25. Epub 2022/07/02. .</Citation><ArticleIdList><ArticleId IdType="pubmed">35777803</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones N, Blagih J, Zani F, Rees A, Hill DG, Jenkins BJ, et al.. Fructose reprogrammes glutamine-dependent oxidative metabolism to support LPS-induced inflammation. Nat Commun. 2021;12(1):1209. Epub 2021/02/24. doi: 10.1038/s41467-021-21461-4 PubMed Central PMCID: PMC7900179 shareholder of GRAIL, and on the science advisory board of PMV Pharma, RAZE Therapeutics, Volastra Pharmaceuticals and Ludwig Cancer. K.H.V. is a co-founder and consultant of Faeth Therapeutics, funded by Khosla Ventures. All other authors declare no competing interests.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21461-4</ArticleId><ArticleId IdType="pmc">PMC7900179</ArticleId><ArticleId IdType="pubmed">33619282</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamyari N, Soltanian AR, Mahjub H, Moghimbeigi A. Diet, Nutrition, Obesity, and Their Implications for COVID-19 Mortality: Development of a Marginalized Two-Part Model for Semicontinuous Data. JMIR Public Health Surveill. 2021;7(1):e22717. Epub 2021/01/14. doi: 10.2196/22717 ; PubMed Central PMCID: PMC7842860.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/22717</ArticleId><ArticleId IdType="pmc">PMC7842860</ArticleId><ArticleId IdType="pubmed">33439850</ArticleId></ArticleIdList></Reference><Reference><Citation>Schurink B, Roos E, Radonic T, Barbe E, Bouman CS, de Boer HH, et al.. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. The Lancet Microbe. 2020;1(7):e290–e9. doi: 10.1016/S2666-5247(20)30144-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30144-0</ArticleId><ArticleId IdType="pmc">PMC7518879</ArticleId><ArticleId IdType="pubmed">33015653</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662–80. Epub 2020/08/06. doi: 10.1038/s41568-020-0285-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41568-020-0285-7</ArticleId><ArticleId IdType="pubmed">32753728</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Xu G, Liao W, Yang H, Xu H, Du S, et al.. Clinicopathologic and prognostic significance of regulatory T cells in patients with hepatocellular carcinoma: a meta-analysis. Oncotarget. 2017;8(24):39658–72. Epub 2017/05/11. doi: 10.18632/oncotarget.17340 ; PubMed Central PMCID: PMC5503641.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.17340</ArticleId><ArticleId IdType="pmc">PMC5503641</ArticleId><ArticleId IdType="pubmed">28487498</ArticleId></ArticleIdList></Reference><Reference><Citation>Posselt R, Erlenbach-Wünsch K, Haas M, Jeßberger J, Büttner-Herold M, Haderlein M, et al.. Spatial distribution of FoxP3+ and CD8+ tumour infiltrating T cells reflects their functional activity. Oncotarget. 2016;7(37):60383–94. Epub 2016/08/06. doi: 10.18632/oncotarget.11039 ; PubMed Central PMCID: PMC5312390.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.11039</ArticleId><ArticleId IdType="pmc">PMC5312390</ArticleId><ArticleId IdType="pubmed">27494875</ArticleId></ArticleIdList></Reference><Reference><Citation>Basse C, Diakite S, Servois V, Frelaut M, Noret A, Bellesoeur A, et al.. Characteristics and Outcome of SARS-CoV-2 Infection in Cancer Patients. JNCI Cancer Spectr. 2021;5(1):pkaa090. Epub 2021/02/20. doi: 10.1093/jncics/pkaa090 ; PubMed Central PMCID: PMC7665636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jncics/pkaa090</ArticleId><ArticleId IdType="pmc">PMC7665636</ArticleId><ArticleId IdType="pubmed">33604509</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Berger NA, Xu R. Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection. JAMA Oncol. 2021;7(2):220–7. Epub 2020/12/11. doi: 10.1001/jamaoncol.2020.6178 ; PubMed Central PMCID: PMC7729584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2020.6178</ArticleId><ArticleId IdType="pmc">PMC7729584</ArticleId><ArticleId IdType="pubmed">33300956</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>